FDAShortage list
FDA declares the semaglutide shortage resolved, winding down compounding
The FDA confirmed the semaglutide shortage was resolved and set deadlines for compounders to stop making copies of the branded GLP-1 drug. Because the exemption allowing 503A and 503B facilities to compound semaglutide depended on its shortage status, removal from the list narrows the legal space in which compounded and “research” semaglutide is supplied.
Source
https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortagesThe issuing body’s own page is authoritative. PepIndex records what it says and when we recorded it; where the two disagree, the source governs.